MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor
- PMID: 16132696
- DOI: 10.1007/s11010-005-3696-6
MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor
Abstract
The tyrosin kinase Met receptor regulates multiple cellular events, ranging from cell motility and angiogenesis to morphological differentiation and tissue regeneration. To conduce these activities, the cytoplasmic C-terminal region of this receptor acts as a docking site for multiple protein substrates, including Grb 2, Gab 1, STAT 3, Shc, SHIP-1 and Src. These substrates are characterised by the presence of multiple domains, including the PH, PTB, SH 2 and SH 3 domains, which directly interact with the multisubstrate C-terminal region of Met. How this receptor recognises and binds a specific substrate in a space-temporal mode is a central question in cell signalling. The recently solved crystal structure of the tyrosine kinase domain of the Met receptor and that of domains of diverse Met substrates provides the molecular framework to understand Met substrate specificity. This structural information also gives new insights on the plasticity of Met signalling and the implications of Met deregulation in tumorigenic processes. In the light of these advances, the present work discusses the molecular basis of Met-substrate recognition and its functional implications in signalling events mediated by this pleiotropic receptor.
(Mol Cell Biochem 276: 143-148, 2005).
Similar articles
-
Non-canonical dynamic mechanisms of interaction between the p66Shc protein and Met receptor.Biochem J. 2016 Jun 1;473(11):1617-27. doi: 10.1042/BCJ20160249. Epub 2016 Apr 5. Biochem J. 2016. PMID: 27048591 Free PMC article.
-
The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.Mol Biol Cell. 1999 Mar;10(3):551-65. doi: 10.1091/mbc.10.3.551. Mol Biol Cell. 1999. PMID: 10069803 Free PMC article.
-
Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.J Biol Chem. 2004 Sep 17;279(38):39915-24. doi: 10.1074/jbc.M404795200. Epub 2004 Jun 24. J Biol Chem. 2004. PMID: 15218027
-
Structural insights into Met receptor activation.Eur J Cell Biol. 2011 Nov;90(11):972-81. doi: 10.1016/j.ejcb.2010.11.014. Epub 2011 Jan 15. Eur J Cell Biol. 2011. PMID: 21242015 Review.
-
Met receptor tyrosine kinase: enhanced signaling through adapter proteins.Oncogene. 2000 Nov 20;19(49):5582-9. doi: 10.1038/sj.onc.1203859. Oncogene. 2000. PMID: 11114738 Review.
Cited by
-
Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.J Biol Chem. 2008 Oct 3;283(40):26985-95. doi: 10.1074/jbc.M805036200. Epub 2008 Jul 14. J Biol Chem. 2008. PMID: 18625714 Free PMC article.
-
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer.Cancers (Basel). 2020 Jun 15;12(6):1575. doi: 10.3390/cancers12061575. Cancers (Basel). 2020. PMID: 32549194 Free PMC article.
-
JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?World J Gastroenterol. 2007 Dec 28;13(48):6478-91. doi: 10.3748/wjg.v13.i48.6478. World J Gastroenterol. 2007. PMID: 18161917 Free PMC article. Review.
-
Design, Synthesis and Biological Evaluation of Multi-Target Anti-Cancer Agent PYR26.Int J Mol Sci. 2023 Apr 12;24(8):7131. doi: 10.3390/ijms24087131. Int J Mol Sci. 2023. PMID: 37108294 Free PMC article.
-
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Cancer Metastasis Rev. 2015 Mar;34(1):19-40. doi: 10.1007/s10555-014-9538-9. Cancer Metastasis Rev. 2015. PMID: 25544368 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous